Skip to content

A study of the efficacy and neural mechanisms of Metacognitive Therapy for adolescents with depression

A study of the efficacy and neural mechanisms of Metacognitive Therapy for adolescents with depression

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090543
Enrollment
Unknown
Registered
2024-10-08
Start date
2024-02-04
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive disorder

Interventions

Metacognitive intervention group:1. Regular medication as prescribed by the clinician 2. Metacognitive therapy group intervention once a week for 1-1.5 hours for six weeks.
Conventional drug group:1. Regular medication as prescribed by the clinician 2. Six weeks of mental health education

Sponsors

Beijing Huilongguan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1) meet the diagnostic criteria of depressive disorder by the Concise International Neuropsychiatric Disorders Interview-Chinese Version 5.0 structured clinical interview; 2) aged 12-18 years old, male or female; 3) no Chinese dyslexia; 4) 17-item Hamilton Depression Scale (HAMD-17) total score of =8; (5) not currently taking psychotropic medication or taking a stable dose of psychotropic medication for at least 6 weeks; (6) willing to participate in the program, and the patient and his/her guardian agreed to participate and signed an informed consent form for the program; (7) able to cooperate with the intervention and complete the entire intervention program.

Exclusion criteria

Exclusion criteria: 1) those with comorbid severe somatic and organic brain disorders; 2) those with comorbid other psychiatric disorders consistent with DSM-5 as well as refractory depression; 3) those who were unable to understand the content of the intervention or who were unable to cooperate due to a variety of uncontrollable factors; 4) those who had been exposed to other metacognition-related interventions in the last 6 months or during the intervention; and 5) those who had a more recent adverse event with a more serious impact or a HAMD-17 Entry 3 (Suicide) Score =3.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale-17,HAMD-17;Hamilton Anxiety Scale,HAMA;fMRI;

Secondary

MeasureTime frame
Meta-cognitions Questionnaire, MCQ-30;Cognitive Emotion Regulation Questionnaire, CERQ;Ruminative Responses Scale;the Child and Adolescent Flexible Expressiveness (CAFE) Scale;The Perceived Stress Scale, PSS-14;Family Adaptability and Cohesion Evaluation Scale;The Reflective Functioning Questionnaire (RFQ-8);Adolescent Non-suicidal Self-injury Assessment Questionnaire,ANSAQ;

Countries

China

Contacts

Public ContactLi jiuju

Beijing Huilongguan Hospital/Peking University Huilongguan Clinical Medical School

271393473@qq.com+86 158 1009 7771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026